AstraZeneca plc (AZN) Stock Rating Reaffirmed by Deutsche Bank AG
AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reissued by analysts at Deutsche Bank AG in a note issued to investors on Wednesday. They presently have a GBX 5,800 ($75.71) price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target suggests a potential upside of 14.04% from the stock’s current price.
A number of other research analysts have also issued reports on AZN. Jefferies Group increased their target price on shares of AstraZeneca plc from GBX 3,900 ($50.91) to GBX 4,100 ($53.52) and gave the stock a “hold” rating in a research report on Tuesday, June 14th. BNP Paribas downgraded shares of AstraZeneca plc to a “neutral” rating and set a GBX 5,200 ($67.88) price target for the company. in a report on Wednesday, September 14th. HSBC reaffirmed a “hold” rating and set a GBX 4,700 ($61.35) price target on shares of AstraZeneca plc in a report on Thursday, August 11th. Beaufort Securities reaffirmed a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Finally, Societe Generale set a GBX 7,000 ($91.37) price target on shares of AstraZeneca plc and gave the stock a “buy” rating in a report on Thursday, September 8th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded up 1.19% during mid-day trading on Wednesday, reaching GBX 5086.00. 3,384,720 shares of the company’s stock were exchanged. The stock has a 50-day moving average of GBX 5,005.11 and a 200-day moving average of GBX 4,435.88. The firm’s market cap is GBX 64.34 billion. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/08/astrazeneca-plc-azn-stock-rating-reaffirmed-by-deutsche-bank-ag.html
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were given a GBX 68.70 ($0.90) dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 11th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.